Skip to content

A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience

From 2019, this study enrolled 20 patients to examine whether Boswellic acids could reduce radiation-induced edema.

Boswellia was administered in a highly bioavailable form, at 4500mg/day throughout the administration of radiation. At the end of the study, the authors noted a sizable proportion showed reduced edema all the while keeping steroid usage stable, low or not used at all.

The latter part is particularly relevant as steroid usage does carry significant side effects and is associated with reduced overall survival, which we explore further in this featured trial.

Share on facebook
Share on email
Share on twitter
Share on linkedin

More on Boswellia

Notify of
Inline Feedbacks
View all comments